US:
Obama will "executive orders" nutzen um das STEM cell programm zu reaktivieren !!!!
Resultate ein paar Tage zuvor:
today reported its financial results for the third quarter ended September 30, 2008.
The Company reported a net loss of $5,744,000, or $0.07 per share, for the third quarter ended September 30, 2008, compared to a net loss of $7,154,000, or $0.09 per share, for the third quarter of 2007. The decrease in net loss in 2008 compared to the same period in 2007 was primarily attributable to a decrease in external services, including costs related to manufacturing and testing of our cell products, as well as lower clinical trial costs. Total revenue for the third quarter of 2008 was $12,000, compared to $13,000 in the third quarter of 2007. Revenue for 2008 and 2007 was from licensing agreements.
Cash, cash equivalents, and marketable debt securities were $21,346,000 at September 30, 2008, compared with $43,294,000 at September 30, 2007. Cash used for operating activities in the third quarter of 2008 was $4,939,000 compared to $4,903,000 in the third quarter of 2007.
auch ansehen:
Cambrex Corporation NYSE
Titan Pharmaceuticals, Inc.
Stem Cell Therapeutics Corp.
Osiris Therapeutics, Inc.
Cytori Therapeutics Inc. (USA)
Neurocrine Biosciences, Inc.
Repligen Corporation NASDAQ
Genzyme Corporation
Acorda Therapeutics Inc.
Neurobiological Technologies, Inc.
Obama will "executive orders" nutzen um das STEM cell programm zu reaktivieren !!!!
Resultate ein paar Tage zuvor:
today reported its financial results for the third quarter ended September 30, 2008.
The Company reported a net loss of $5,744,000, or $0.07 per share, for the third quarter ended September 30, 2008, compared to a net loss of $7,154,000, or $0.09 per share, for the third quarter of 2007. The decrease in net loss in 2008 compared to the same period in 2007 was primarily attributable to a decrease in external services, including costs related to manufacturing and testing of our cell products, as well as lower clinical trial costs. Total revenue for the third quarter of 2008 was $12,000, compared to $13,000 in the third quarter of 2007. Revenue for 2008 and 2007 was from licensing agreements.
Cash, cash equivalents, and marketable debt securities were $21,346,000 at September 30, 2008, compared with $43,294,000 at September 30, 2007. Cash used for operating activities in the third quarter of 2008 was $4,939,000 compared to $4,903,000 in the third quarter of 2007.
auch ansehen:
Cambrex Corporation NYSE
Titan Pharmaceuticals, Inc.
Stem Cell Therapeutics Corp.
Osiris Therapeutics, Inc.
Cytori Therapeutics Inc. (USA)
Neurocrine Biosciences, Inc.
Repligen Corporation NASDAQ
Genzyme Corporation
Acorda Therapeutics Inc.
Neurobiological Technologies, Inc.